Purchase this article with an account.
Nikisha Kothari, Deborah Chong, Robert Wang, Christopher Fuller, Ashkan Abbey; Fluticasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3314.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the outcomes of use of the fluticasone acetate implant in eyes with macular edema from retinal vein occlusion.
We retrospectively reviewed 13 eyes with macular edema from retinal vein occlusion who received an injection with the fluticasone implant. We evaluated visual acuity and central retinal thickness outcomes and documented complications including cataract progression and increased intraocular pressure (IOP).
Visual acuity improved following injection with the fluticasone implant at final follow up (0.39 vs 0.26, p= 0.02). In addition, central retinal thickness improved by 6 months, but then increased by final follow up (412mm, 302mm p=0.01, 345mm p=0.3). In all phakic patients, cataract progression was seen and required phacoemulsification surgery. Seven (53%) patients required IOP lowering medications and two (15%) required glaucoma filtration surgery.
Our study found the use of the fluticasone implant to be safe and effective for the management of macular edema from retinal vein occlusion. Further larger, randomized controlled studies are required to further evaluate their efficacy.
This is a 2021 ARVO Annual Meeting abstract.
This PDF is available to Subscribers Only